AYTU (MC $13 M) (Cash $15 M) MEGA Drug launch in July ($2+ BILLION Market)

Discussion in 'Stock picks and trading strategies' started by DollarChamp, May 26, 2016.

  1. DollarChamp

    DollarChamp Member

    Here is an undiscovered Stock with Monster Upside Potential which just trading at cash level . Aytu Biosciences bought US Rights to Natesto the only approved testosterone nasal gel which targets a $2+ BILLION Market which they start selling in July . The Company has another 3 Products on the Market and another One Big drug ready for Phase 3 . AYTU has a ridiculous Market Cap of just $13 Million which is below the Cash balance of $15 Million means you get the Company and Products for free . The Stock has minumum upside Potential of 700%+ .

    In April, AYTU signed an exclusive license agreement for the U.S. commercial rights to Natesto® (testosterone) Nasal Gel. Natesto is the first and only nasal formulation of testosterone approved by the U.S. Food and Drug Administration (FDA) as a replacement therapy for men diagnosed with hypogonadism (low testosterone, or “Low T”). Aytu anticipates further expanding its current urology-centric sales force and initiating its promotion of Natesto into the $2 billion U.S. testosterone replacement market in July 2016.

    Aytu Bioscience (AYTU)

    Market Cap: $13.5 Million
    Cash: $15 Million
    Price: $0.30

    Shares Out: 44.86 Million

    Marketed Products:

    PRIMSOL : Only FDA-approved trimethoprim oral solution; indicated for urinary tract infections

    ProstaScint : Only FDA-approved imaging agent for prostate cancerdetection and staging

    MIOXSYS : CE Marked in vitro diagnostic device for male infertility , Single FDA study pending

    Acquired Exclusive U.S. Rights to Natesto April 2016 (US Market Launch July)

    •Only FDA-approved, nasally-administered testosterone; indicated for hypogonadism
    •Approved for use WITHOUT black box warning related to partner transference

    ZERTANE :phase 3-ready, effective first-in-class oral treatment for premature ejaculation

    Presentation May 2016

    Aytu BioScience Initiates Commercial Expansion to Support July 2016 Launch of Natesto®

    Insider Buying:

    May 6, 2016 DISBROW JOSHUA R. Officer direct Buy 0.40 250,000

    May 6, 2016 DISBROW JARRETT Officer direct Buy 0.40 250,000

    May 6, 2016 DOCKERY CARL Director indirect Buy 0.40 5,000,000

    Jan 20, 2016 DISBROW JOSHUA R. Officer direct Buy 0.65 153,846

    Jan 20, 2016 DISBROW JARRETT Officer direct Buy 0.65 153,846

Share This Page